A Phase 2 interventional study of Psilocybin, 1.5 mg in Fragile X Syndrome, Behavior and Cognitive Dysfunction, sponsored by Nova Mentis Life Science Corp. Suspended at 1 site in Canada. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-05-08.
Sponsored by Nova Mentis Life Science Corp · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Fragile X Syndrome with a site in Canada — 2 open to participants now, 2 under way, none of them phase 3. Fragile X Syndrome · Canada.
Among the 12 studies in Fragile X Syndrome with a site in Canada, this one is the 12th largest by planned enrollment, is the only one that started in 2023, is one of 10 in phase 2, and was the 10th registered.
115 studies on the registry are indexed under Fragile X Syndrome; 25 are open to participants now.
Browse Fragile X Syndrome studies →2 of the 12 studies in Fragile X Syndrome with a site in Canada are open now. Recruiting first, the newest first:
Université de Sherbrooke · Sites in Canada
Ages 7–40
Holland Bloorview Kids Rehabilitation Hospital · Sites in Canada
Ages 8–17
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 18 Fragile X Syndrome studies recruiting now, 5 (28%) set no upper age limit and 13 (72%) stop at 75 or younger; 15 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 11 · Phase 3 1
First in 2007; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 54 across 92 interventional studies indexed under Fragile X Syndrome.
Median enrollment 123 across the 12 interventional studies. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 12 have an industry lead sponsor. The 8 most frequent:
Nova Mentis Life Science Corp is the lead sponsor of 2 studies on the registry; none are open to participants now.
Nova Mentis Life Science Corp has 2 studies filed under Fragile X Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Fragile X Syndrome with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06081348Holland Bloorview Kids Rehabilitation HospitalSertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Fragile X Syndrome with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Diverse symptomatology makes Fragile X Syndrome (FXS) difficult to treat, and currently there are no approved prevention or treatment methods for FXS. Current therapies, including pharmaceutical and behavioural interventions, offer a patchwork of solutions that have limited efficacy and high toxicity. The current study aims to examine psilocybin as a safe treatment alternative with the ability to improve markers of cognition, communication, mood, behavior as well as markers of neuroinflammation, serotonin levels in exosomes, and neuroplasticity at sub-hallucinogenic doses (microdosing).
The overall objective of this study is to assess the feasibility of low-dose psilocybin as a therapeutic option for individuals living with FXS and to improve diagnostic parameters of FXS, as well as therapeutic responses with the use of biomarkers.
A total of 10 subjects who meet all the inclusion criteria and does not meet any of the exclusion criteria will be enrolled into the study. Any subjects prematurely terminated from the study will be replaced to ensure 10 subjects complete the study. A study coordinator will contact referring clinicians, caregivers, and subjects to pre-screen for initial eligibility. Those deemed eligible will be invited for an in-person screening along with the participating caregiver. The screening visit will be approximately two hours long and will consist of informed consent, diagnostic interview, physical examination, drugs of abuse test (DOA), ECG, medical/treatment history review, and demographic forms. A pregnancy test will be performed on females of child-bearing during screening, baseline, and end-of-study visits. All eligible subjects will enter the treatment arm of the study.
Subjects and caregivers will return to the clinic for a baseline visit within three weeks of their screening completion. Baseline visit will include saliva/buccal swab collection, and clinician and self-report assessments for subjects and caregivers. These assessments will include the Vineland Adaptive Behavior Scales-Third Edition (VABS-3), Clinical Global Impressions-Improvement scale (CGI-I), Visual Analog Scale-Treatment Satisfaction (VAS-TS), the Anxiety, Depression and Mood Scale (ADAMS), and the Systematic Assessment For Treatment Emergent Events (SAFTEE). Digital assessments may also be performed at the baseline visit or at home at the discretion of the qualified investigator. Digital assessments will include the NIH Toolbox Cognitive Battery Modified for Intellectual Disabilities (NIH-TCB), the Trail Making Test (TMT), and the Multifaceted Empathy Test (MET).
The study drug will be dispensed in blister packs to monitor adherence and improve subject compliance. Blister packs will be prepared and distributed at each subsequent visit. Subjects will return to the clinic for study visits on day 8, 15, 22, and 28 (study end date). Subjects and caregivers will complete the assessments described above. Subjects will provide additional saliva/buccal swab samples at day 15 and day 28.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject has the ability to understand and provides voluntary, written, to participate in the study
Or,
For subjects who are not their own legal guardian, or do not have the capacity to provide informed consent, subject's parent/legal authorized guardian is able to understand and sign an informed consent form to participate in the study.
Or,
Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will take one capsule containing 1.5 mg psilocybin with a glass of water every other day for a period of 28 days. Dosing schedule will be same for all participants with the drug taken at days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, and no treatment taken on alternating days. No subject shall be provided with more than five capsules (7.5mg psilocybin) at any one time to prevent diversion to the illicit market. If a dose is missed, participants are instructed to skip that dose and continue with their regularly scheduled medications. Participants are not to take \>1 capsule per day.
Drug: Psilocybin, 1.5 mg
Blister packs will contain five capsules of the study drug, Psilocybin 1.5mg. Subjects will be given blister packs with weekly doses at each visit including baseline (day 1), day 8, day 15, day 21, and day 28. Weekly blister packs will contain five doses (1-2 extra capsules depending on the week) to accommodate for flexibility in scheduling. Unused and open packages will be returned to study staff at each visit after baseline.
Retention rate associated with 10 participants progressing to study completion.
Study completion is defined as completing the 28-day treatment period and the final in-clinic study visit.
Time frame: baseline to day 28
Compliance with study dosing regimen as measured by the Visual Analogue Scale for Dosing (VAS-D).
Participants will be monitored for compliance using electronic compliance checks via the remote patient reported outcomes system through recording consumption in the treatment diary. Participants and caregivers will receive daily notifications via their preferred format (i.e., email, text) during agreed upon dosage windows. Notification will include a reminder to complete a post-dosage Visual Analogue Scale for Dosing (VAS-D) to monitor for any side effects which can be submitted electronically. Failure to complete the VAS-D within the day of dosing will trigger a call from study personnel to the participant in order to do a compliance check. Study personnel will note any deviations and all points of contact with participants regarding compliance checks.
Time frame: baseline to day 28
Compliance with study dosing regimen as measured by the quantity of unused investigational product returned to the study clinic.
Time frame: baseline to day 28
Adherence with completion of diaries monitoring participant and caregiver reported outcomes.
Adherence with study requirements for patient reported and caregiver reported outcomes (i.e., diaries) will be monitored using a remote patient reported outcomes system. Adherence will be assessed by determining the number of completed patient/caregiver diaries divided by the number of diaries expected to be completed.
Time frame: baseline to day 28
Adherence with completion of questionnaires monitoring participant and caregiver reported outcomes.
Adherence with study requirements for patient reported and caregiver reported outcomes (i.e., questionnaires) will be monitored using a remote patient reported outcomes system. Adherence will be assessed by determining the number of completed patient/caregiver questionnaires divided by the number of questionnaires expected to be completed.
Time frame: baseline to day 28
The number of late entries for diaries monitoring patient reported and caregiver reported outcomes.
Time frame: baseline to day 28
The number of late entries for questionnaires monitoring patient reported and caregiver reported outcomes.
Time frame: baseline to day 28
Satisfaction with study questionnaire.
Time frame: baseline to day 28
Change from baseline in standardized measures of behavioral rigidity using the ratings of repetitive and stereotyped behaviors from the revised Repetitive Behavior Scale (RBS-R).
Time frame: baseline, day 15, day 28
Change in standardized measures of empathy using the communication domain of the Vineland Adaptive Behavior Scales- Third Edition (VABS-3).
Time frame: baseline, day 15, day 28
Change in standardized measures of empathy using the overall score on the Multifaceted Empathy Test (MET).
Time frame: baseline, day 15, day 28
Change in standardized measures of expressive and receptive language skills using the communication domain of the Vineland Adaptive Behavior Scales- Third Edition (VABS-3).
Time frame: baseline, day 15, day 28
Change in standardized measures of expressive and receptive language skills using the overall score on the Multifaceted Empathy Test (MET).
Time frame: baseline, day 15, day 28
Changes in standardized measures of behavioral symptoms as measured by the Aberrant Behavior Checklist (ABC) with particular focus on ratings of repetitive/ritualistic behaviors from baseline to end of study.
Time frame: baseline, day 8, day 15, day 21, day 28
Changes in standardized measures of behavioral symptoms as measured by the Aberrant Behavior Checklist (ABC) with particular focus on ratings of aggressive behaviors from baseline to end of study.
Time frame: baseline, day 8, day 15, day 21, day 28
Changes in standardized measures of behavioral symptoms as measured by the revised Repetitive Behavior Scale (RBS-R) with particular focus on ratings of repetitive/ritualistic behaviors from baseline to end of study.
Time frame: baseline, day 8, day 15, day 21, day 28
Changes in standardized measures of behavioral symptoms as measured by the revised Repetitive Behavior Scale (RBS-R) with particular focus on ratings of aggressive behaviors from baseline to end of study.
Time frame: baseline, day 8, day 15, day 21, day 28
Changes in standardized measures of behavioral symptoms as measured by the Clinical Global Impressions (CGI) scale with particular focus on ratings of repetitive/ritualistic behaviors from baseline to end of study.
Time frame: baseline, day 8, day 15, day 21, day 28
Changes in standardized measures of behavioral symptoms as measured by the Clinical Global Impressions (CGI) scale with particular focus on ratings of aggressive behaviors from baseline to end of study.
Time frame: baseline, day 8, day 15, day 21, day 28
Changes in standardized measures of behavioral symptoms with particular focus on ratings of aggressive behaviors from baseline to end of study.
Changes in behavioral symptoms will be measured via the Aberrant Behavior Checklist (ABC), revised Repetitive Behavior Scale (RBS-R), and Clinical Global Impressions (CGI) scale.
Time frame: baseline, day 8, day 15, day 21, day 28
Changes in overall cognition scores as measured by the NIH Toolbox Cognitive Battery Modified for Intellectual Disabilities (NIH-TCB).
Time frame: baseline, day 28
Changes in overall cognition scores as measured by the Trail Making Test (TMT)-digital version.
Time frame: baseline, day 28
Changes in overall cognition scores as measured by the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A).
Time frame: baseline, day 28
Changes in standardized measures of cognitive flexibility as measured by the NIH Toolbox Cognitive Battery Modified for Intellectual Disabilities (NIH-TCB) from baseline to end of study.
Time frame: baseline, day 28
Changes in standardized measures of cognitive flexibility as measured by the Trail Making Test (TMT)-digital version from baseline to end of study.
Time frame: baseline, day 28
Changes in standardized measures of cognitive flexibility as measured by the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) from baseline to end of study.
Time frame: baseline, day 28
Changes in standardized measures of anxiety and depression with corresponding changes in ratings of overall wellbeing.
Changes in anxiety, depression, and overall wellbeing will be measured via the Anxiety, Depression and Mood Scale (ADAMS).
Time frame: baseline, day 8, day 15, day 21, day 28
To improve diagnostic phenotyping of FXS through analysis of biomarkers using buccal swab and saliva samples.
Machine learning algorithms will be applied to analyze and establish clustering and/or correlation between diverse datasets to help stratify adults with FSX according to subtle differences in mRNA neuroinflammatory biomarkers, serotonin signaling, and behavior.
Time frame: baseline, day 15, day 28
To characterize the role of psilocybin as a modulator of neuroinflammation through analysis of mRNA neuroinflammatory biomarkers using saliva samples from baseline to study end.
mRNA analysis will include a panel with 52 genes including cytokines, cytokine targets, neurotransmission, serotonin signaling, membrane channel, DNA damage repair, and growth factors.
Time frame: baseline, day 15, day 28
To characterize the role of psilocybin as a modulator of neuroinflammation through analysis of mRNA neuroinflammatory biomarkers using buccal swabs from baseline to study end.
mRNA analysis will include a panel with 52 genes including cytokines, cytokine targets, neurotransmission, serotonin signaling, membrane channel, DNA damage repair, and growth factors.
Time frame: baseline, day 15, day 28
To characterize the role of psilocybin as a modulator of neuroinflammation through analysis of serotonin levels using saliva samples from baseline to study end.
Time frame: baseline, day 15, day 28
To characterize the role of psilocybin as a modulator of neuroinflammation through analysis of serotonin levels using buccal swabs from baseline to study end.
Time frame: baseline, day 15, day 28
The incidence of pre-emergent and post-emergent adverse events.
Time frame: baseline to 28 days
The incidence of clinically significant changes in blood pressure (BP).
Time frame: baseline, day 8, day 15, day 21, day 28
The incidence of clinically significant changes in heart rate (HR).
Time frame: baseline, day 8, day 15, day 21, day 28
Started Mar 2023 (actual). Primary completion is estimated for May 2024, 14 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is suspended, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Psilocybin
Nova Mentis Life Science Corp